| Name | Title | Contact Details |
|---|
Brain TunnelGenix Technologies Corp is a Bridgeport, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ONI is a pioneer of next generation super-resolution microscopy, making this advanced technology accessible to new generations of researchers. The Nanoimager, the world`s first benchtop sized super-resolution microscope, delivers a step change in usability and precision. The microscope offers easy access to a range of super-resolution techniques including dSTORM and PALM, as well as smFRET, single-particle tracking and confocal. The company`s achievements have been recognised by FastTrack100 who named ONI on their 2018 list of 10 Disruptors to Watch and ONI won Best Business Start-up at the 2018 IOP Awards. More and more life science researchers and pharma companies are taking an interest in ONI and it now has customers using its products in leading laboratories across the globe, including the Universities of Oxford, Cambridge and Harvard. ONI has a restless enthusiasm to make the world a better place. Our ambition is to bring super-resolution fluorescence imaging to a new community of researchers and we are removing barriers to make science more effective, accessible and affordable. We have a vision for making high tech science available to anyone, anywhere, from the research bench to your doctor`s office.
Stembanc is a Chardon, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioEnterprise Corporation is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company`s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, MD Anderson Cancer Center and ImmunoGen, Inc.